VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Insights into the DREAMM-14 trial

Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, briefly discusses the DREAMM-14 trial (NCT05064358), which is evaluating different dosing regimens of belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM), with the main aim of minimizing the ocular toxicity associated with this agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research Funding: GSK, Amgen, Daiichi Sankyo, Cosette
Advisory board: BMS
Consultancy: Curio Science LLC, Intellisphere LLC
Membership on an entity’s Board of Directors or advisory committees: GSK

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter